Becker's Healthcare February 16, 2024
A week ahead of schedule, the FDA approved the nation’s first cell therapy for advanced melanoma on Feb. 16.
The drug, Iovance Biotherapeutics’ Amtagvi, is a tumor-derived autologous T cell immunotherapy that expands a patient’s own T cells to fight the cancer.
The medicine is indicated for unresectable or metastatic melanoma, which...